[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353030-105":59,"doc-detail-353030-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","survival-following-sublobar-resection-after-neoadjuvant-therapy-for-t1n1-2m0-lung-cancer","Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer","","Lobectomy is standard for resectable non-small cell lung cancer, yet sublobar resection is increasingly used for small, early tumors. The study evaluates whether sublobar surgery after neoadjuvant therapy changes outcomes for patients with T1N1-2M0 NSCLC. Using the National Cancer Database (2011–2021), survival after sublobar resection (wedge or segmentectomy) is compared with lobectomy following neoadjuvant chemotherapy, chemoradiation, or chemoimmunotherapy. Kaplan–Meier and multivariable Cox regression assess overall survival while accounting for clinical stage and treatment timing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/survival-following-sublobar-resection-after-neoadjuvant-therapy-for-t1n1-2m0-lung-cancer/353030/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/survival-following-sublobar-resection-after-neoadjuvant-therapy-for-t1n1-2m0-lung-cancer/353030.png","ImageObject",300,407,{"name":92,"@type":93},"supergirl","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical question does the study address?","Question",{"text":112,"@type":113},"It compares survival after sublobar resection versus lobectomy in patients with T1N1-2M0 NSCLC treated with neoadjuvant therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were patients selected and grouped?",{"text":117,"@type":113},"Patients (≥18 years) with clinical stage T1N1-2M0 NSCLC who received neoadjuvant therapy and underwent resection within 8 months were identified from the National Cancer Database; they were grouped as sublobar (wedge/segmentectomy) versus lobectomy.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main survival and perioperative findings?",{"text":121,"@type":113},"Sublobar resection involved fewer lymph nodes examined and shorter hospital stays, with stage II–III showing comparable one-year survival; however, long-term survival at 5 years was lower for stage III after adjusted analysis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353030,1790172666,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","OPEN ACCESS  \nCitation: Reddington H, Emmerick I, Diaz Collante J, Maini A, Kanzaria R, Crawford A, et al. (2026) Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer. PLoS One 21(6): e0349231. [https://doi](https://doi). org/10.1371/journal.pone.0349231  \nEditor: Luca Bertolaccini, European Institute of Oncology: Istituto Europeo di Oncologia, ITALY  \nReceived: January 8, 2026  \nAccepted: April 27, 2026  \nPublished: June 3, 2026  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: [https://doi.org/10.1371/journal](https://doi.org/10.1371/journal). pone.0349231  \nCopyright: © 2026 Reddington et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution,  \nRESEARCH ARTICLE  \nSurvival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer  \nHayley Reddington1☯, Isabel Emmerick1☯, Javier Diaz Collante1☯, Aniket Maini2☯, Raghav Kanzaria2☯, Allison Crawford2, William Phillips1, Mark Maxfield1, Karl Uy1, Feiran Lou1¤*  \n1 Department of Surgery, Division of Thoracic Surgery, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America, 2 University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America  \n☯ These authors contributed equally to this work.  \n¤ Current address:University of Massachusetts Chan Medical School, Department of Thoracic Surgery, Worcester, Massachusetts, United States of America  \n* [Feiran.lou@umassmemorial.org](Feiran.lou@umassmemorial.org)  \nAbstract  \nBackground  \nLobectomy remains the standard surgical approach for resectable non-small cell lung cancer (NSCLC), but sublobar resection is increasingly considered, particularly for small, early-stage tumors. The role of sublobar resection after neoadjuvant therapy is unclear. We compared survival after sublobar resection versus lobectomy among patients with T1N1-2M0 NSCLC treated with neoadjuvant therapy.  \nMethods  \nUsing the National Cancer Database (2011–2021), we identified patients ≥18 years with clinical stage T1N1-2M0 NSCLC who received neoadjuvant chemotherapy, chemoradiation, or chemoimmunotherapy followed by resection within 8 months. Patients with pneumonectomy, metastases, positive margins were excluded. Patients were grouped by resection type: sublobar (wedge or segmentectomy) vs. lobectomy (including bilobectomy and extended) . Survival was assessed via Kaplan–Meier analysis and multivariable Cox regression.  \nResults  \nOf 2,257 patients, 148 (6 .6%) underwent sublobar resection. Compared to lobectomy, sublobar resection was associated with fewer lymph nodes examined (24% vs. 54% with >10 nodes, p \u003C 0.001) and shorter hospital stays (3 .9 vs. 5.3 days, p \u003C 0.001) . Stage distribution was similar. One-year survival was comparable for both groups in stage II and III disease. At 5 years, survival was lower for stage III patients  \nPLOS One | [https://doi.org/10.1371/journal.pone.0349231](https://doi.org/10.1371/journal.pone.0349231) June 3, 2026 1 / 13  \nand reproduction in any medium, provided the original author and source are credited.  \nData availability statement: The data underlying this study were obtained from the National Cancer Database (NCDB) Participant User File (PUF), a program administered jointly by the American College of Surgeons and the American Cancer Society. The authors do not have the right to publicly share the NCDB dataset used in this study with anyone not on the Participant User File (PUF) agreement, per NCDB policy. The dataset may be requested from the NCDB via [NCDB_PUF@facs.org](NCDB_PUF@facs.org) after completing the PUF application process at  \n[https://www.facs.or","cbCaijpR6raMjSkD","https://ap.wps.com/l/cbCaijpR6raMjSkD","pdf",671634,13,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"What clinical question does the study address?\",\"answer\":\"It compares survival after sublobar resection versus lobectomy in patients with T1N1-2M0 NSCLC treated with neoadjuvant therapy.\"},{\"question\":\"How were patients selected and grouped?\",\"answer\":\"Patients (≥18 years) with clinical stage T1N1-2M0 NSCLC who received neoadjuvant therapy and underwent resection within 8 months were identified from the National Cancer Database; they were grouped as sublobar (wedge/segmentectomy) versus lobectomy.\"},{\"question\":\"What were the main survival and perioperative findings?\",\"answer\":\"Sublobar resection involved fewer lymph nodes examined and shorter hospital stays, with stage II–III showing comparable one-year survival; however, long-term survival at 5 years was lower for stage III after adjusted analysis.\"}]","Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer | PDF",1790102664,33]